Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds.

Int J Mol Sci

Institute of Medical Sciences, Tzu Chi University, Hualien 97004, Taiwan.

Published: March 2022

Hepatitis is defined as inflammation of the liver; it can be acute or chronic. In chronic cases, the prolonged inflammation gradually damages the liver, resulting in liver fibrosis, cirrhosis, and sometimes liver failure or cancer. Hepatitis is often caused by viral infections. The most common causes of viral hepatitis are the five hepatitis viruses-hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), and hepatitis E virus (HEV). While HAV and HEV rarely (or do not) cause chronic hepatitis, a considerable proportion of acute hepatitis cases caused by HBV (sometimes co-infected with HDV) and HCV infections become chronic. Thus, many medical researchers have focused on the treatment of HBV and HCV. It has been documented that host lipid metabolism, particularly cholesterol metabolism, is required for the hepatitis viral infection and life cycle. Thus, manipulating host cholesterol metabolism-related genes and proteins is a strategy used in fighting the viral infections. Efforts have been made to evaluate the efficacy of cholesterol-lowering drugs, particularly 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, in the treatment of hepatitis viral infections; promising results have been obtained. This review provides information on the relationships between hepatitis viruses and host cholesterol metabolism/homeostasis, as well as the discovery/development of cholesterol-lowering natural phytochemicals that could potentially be applied in the treatment of viral hepatitis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999150PMC
http://dx.doi.org/10.3390/ijms23073897DOI Listing

Publication Analysis

Top Keywords

hepatitis virus
16
hepatitis
14
viral hepatitis
12
viral infections
12
cholesterol metabolism
8
cholesterol-lowering natural
8
hepatitis viral
8
host cholesterol
8
viral
7
virus
5

Similar Publications

Coronaviruses (CoVs) encode non-structural proteins (nsp's) 1-16, which assemble to form replication-transcription complexes that function in viral RNA synthesis. All CoVs encode a proofreading 3'-5' exoribonuclease in non-structural protein 14 (nsp14-ExoN) that mediates proofreading and high-fidelity replication and is critical for other roles in replication and pathogenesis. The enzymatic activity of nsp14-ExoN is enhanced in the presence of the cofactor nsp10.

View Article and Find Full Text PDF

Background: Restrictive Medicaid policies regarding hepatitis C virus (HCV) treatment may exacerbate rural health care disparities for people who use drugs (PWUD). We assessed associations between Medicaid restrictions and HCV treatment among rural PWUD.

Methods: We compiled state-specific Medicaid treatment policies across 8 US rural sites in 10 states and merged these with participant survey data.

View Article and Find Full Text PDF

: Direct-acting antiviral agents (DAAs) have significantly reduced Hepatitis C Virus (HCV) transmission and improved health outcomes since their FDA approval in 2011. Despite these advances, over 70 million people remain untreated globally, with a disproportionately high burden in low- and middle-income countries (LMICs). : Through a structured search of open access informational sources and an informal peer-reviewed literature review, HCV treatment barriers were identified, compiled, and analyzed.

View Article and Find Full Text PDF

Objective: This study aimed to investigate hepatitis B knowledge and hepatitis B virus (HBV)-related surveillance status among HBsAg-positive patients, as well as to further explore the relevant influencing factors.

Methods: A cross-sectional study was conducted on the HBsAg-positive patients from 8 October 2023 to 10 November 2023 in Qidong City. A self-report questionnaire was developed based on a literature review of similar studies.

View Article and Find Full Text PDF

Tenofovir vs. Entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma patients after liver resection: the role of HBsAg levels.

Clin Transl Gastroenterol

January 2025

Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Background: Our study aimed to explore whether hepatitis B surface antigen (HBsAg) levels affected the role of nucleot(s)ide analog treatment (entecavir (ETV) and tenofovir (TDF)) in improving the prognosis of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients after liver resection.

Methods: A total of 865 HBV-related HCC patients after hepatectomy treated with TDF or ETV were included in our study. Patients were divided into the high HBsAg cohort (n=681) and the low HBsAg cohort (n=184).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!